The present invention relates to: a method for screening an antifungal agent, the method measuring the amount or activity of proteins involved in passage through the brain-blood barrier; a biomarker composition for diagnosing meningoencephalitis or cryptococcosis; a diagnostic kit including said composition; and a therapeutic pharmaceutical composition including an inhibitor for the protein.

Provided is a drug target for vitiligo. The drug target is IFN-γ signaling. It also provides a method for establishing vitiligo animal model, or a vitiligo induction method in an animal, and the established vitiligo animal model. Further, provided is a method for screening candidate drugs for treating vitiligo using the said animal model.

A chimeric non-human mammal disease model, wherein (1) at least 30% of all the glial cells in the corpus callosum of the chimeric non-human mammal are human glial cells, and/or (2) at least 5% of all of the glial cells in the white matter of the brain and/or brain stem of the chimeric non-human mammal are human glial cells, and wherein the human glial cells comprise a combination of a first group of human glial cells tagged with a first label and a second group of human glial cells tagged with a second label that is distinguishable from the first label.

The present disclosure relates to the genetically modified non-human animals that express a human or chimeric TIGIT (e.g., humanized TIGIT), and methods of use thereof.

Described herein are rats with a hepatic deficiency comprising decreased function, activity, or expression of an enzyme in the tyrosine catabolic pathway (such as fumarylacetoacetate hydrolase), and methods of using the same for in vivo engraftment and expansion of heterologous hepatocytes, such as human hepatocytes, analysis of human liver disease, and analysis of xenobiotics. Also disclosed is the use of immunodeficient rats for the engraftment and expansion of heterologous hepatocytes.

Synthetic adenoviruses with liver detargeting mutations and expressing an adenovirus type 34 (Ad34) fiber protein, or a chimeric fiber protein with an Ad34 knob domain, are described. The synthetic adenoviruses traffic to sites of tumors. Use of the synthetic adenoviruses for delivering diagnostic or therapeutic transgenes to tumors are also described.

Provided is an epithelial tissue stem cell derived from an adult, which lacks at least one tumor suppressor gene.

Provided herein are compositions and methods for producing genomically edited cells expressing an exogenous transgene and restored or continued expression of an endogenous gene. Methods of using the genomically edited cells for treating or preventing a disease in a subject are also provided.

The present invention relates to a method for producing an avatar mouse, which is an animal model of atopic dermatitis, and a method of screening a therapeutic agent for atopic dermatitis using the same. According to the present invention, it is possible to more effectively identify a patient-specific immune response by representing an immune response in an actual atopic dermatitis patient. Thus, the present invention is expected to be widely used in the development of a new immunotherapy system enabling tailored treatment.

The present invention relates to a method for preparing a large animal model, with peritoneal carcinomatosis, which is an abdominal cavity metastasis of tumor commonly found in advanced or recurrent solid cancer, is induced using a large animal, and the method for preparing a large animal model with peritoneal carcinomatosis comprises injecting a cancer cell line into the abdominal cavity of a piglet in which the immune function is not completed. The method for preparing a large animal model with peritoneal carcinomatosis, when a human-derived immortalized cell line is inoculated into a pig, can overcome xenograft rejection and induce peritoneal carcinomatosis, can use animals with sufficient supply and demand, and can expect the spread of peritoneal carcinomatosis through breeding.